List view / Grid view
Bioactivity profiling has been traditionally used to assess the selectivity of new drug candidates in the context of target-based approaches, where pharmacological selectivity is a key requirement.
27 April 2018 | By Eurofins Pharma Discovery Services
In this webinar, we discussed a recent case study where a phenotypic screen was performed using poly I:C / IL-4 stimulated human bronchial epithelial cells. This resulted in the identification of 7 representative hits which provided starting points for new drug discovery opportunities.
Scientists have built a computational microscope that can simulate the atomic and subatomic forces that drive molecular interactions...
New technology could lead to the development of new cancer therapies...
Researchers uncover four microRNA molecules in the bloodstream that could predict the onset of atrial fibrillation...
Two distinctive handfuls of short molecules that regulate gene expression have been found in the eye fluid of patients with two distinct types of vision degenerating glaucoma.
A microRNA that regulates inflammation shows promise as a treatment for inflammatory diseases such as asthma and cancer...
Presenting issues and real-life examples within the RNA space, SMi welcome insights and discussions into new technologies for single-stranded RNA, epigenetics to develop first-in class drugs in oncology, patenting RNA Therapeutics and exploring the latest developments in delivery systems, including Exosomes and Nanocomplexes. Read on for your exclusive discount to…
A team of researchers led by IRB Barcelona in Spain have identified a key function of the enzyme EXD2 as being the maintenance of protein production in the mitochondria.
Survival rates in pancreatic cancer linked to the inverse correlation between specific oncogene and tumour suppressant microRNA...
Researchers have presented a systematic catalogue of specific variable locations in the genome that influence gene activity in the human hippocampus...
Researchers have successfully reversed type 1 diabetes by infusing blood stem cells pre-treated to produce more PD-L1...
A team of researchers have developed a new technology, which is promising to understand and treat ischemic diseases...
SMi are delighted to have, Nagy Habib, Head of HPB Surgery, Imperial College London and Co-Founder, MiNA Therapeutics, as the Keynote Address for day 1 at RNA Therapeutics 2018!
